Go Pro
OTCMKTS:SIGY

Sigyn Therapeutics Q3 2025 Earnings Report

Sigyn Therapeutics logo
$0.03 0.00 (0.00%)
As of 09/25/2026

Sigyn Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sigyn Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sigyn Therapeutics Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sigyn Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026, based on past reporting schedules.

Conference Call Resources

Sigyn Therapeutics Earnings Headlines

SIGY Sigyn Therapeutics Inc.
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Sigyn Therapeutics Delays Annual SEC Filing
See More Sigyn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email.

About Sigyn Therapeutics

Sigyn Therapeutics (OTCMKTS:SIGY) is a biotechnology company developing therapeutic technologies for life-threatening conditions involving excessive inflammation and circulating pathogens. Its lead product candidate, Sigyn Therapy, is an investigational blood-purification device designed to remove inflammatory cytokines and pathogen-associated toxins from a patient’s blood.

The company is evaluating Sigyn Therapy for potential use in conditions such as cytokine storm and endotoxemia, including inflammatory complications associated with severe infections and other diseases. The technology is intended to support the body’s immune response by reducing harmful substances in the bloodstream, but it remains under development and has not been established as an approved treatment.

Sigyn Therapeutics is headquartered in the United States and focuses primarily on advancing its platform through research, development and potential clinical applications. Publicly available information about the company’s commercial operations, geographic reach and current leadership is limited.

View Sigyn Therapeutics Profile